Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Drug	Reports	Deaths	Death Rate	Hosp.	Life-Threat.	Avg Age	% Female
EFAVIRENZ	7,893	962	12.2%	1,528	252	40.7 yrs	37.7%
RILPIVIRINE	7,049	196	2.8%	593	109	45.8 yrs	29.5%
NEVIRAPINE	6,651	1,101	16.6%	979	152	35.8 yrs	45.5%
ETRAVIRINE	1,969	257	13.1%	405	74	47.5 yrs	33.5%
DORAVIRINE	442	50	11.3%	94	11	55.7 yrs	23.1%

Head-to-Head Comparisons

EFAVIRENZ vs RILPIVIRINE EFAVIRENZ vs NEVIRAPINE EFAVIRENZ vs ETRAVIRINE EFAVIRENZ vs DORAVIRINE RILPIVIRINE vs NEVIRAPINE RILPIVIRINE vs ETRAVIRINE RILPIVIRINE vs DORAVIRINE NEVIRAPINE vs ETRAVIRINE NEVIRAPINE vs DORAVIRINE ETRAVIRINE vs DORAVIRINE

← Back to Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Class side effects →